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Abstract
Introduction:  Asthma  is  a  chronic  inflammatory  airways  disease  associated  with  reversible  airflow  obstruction  and  bronchial 
hyperresponsiveness. Asthma is prevalent worldwide and results in significant morbidity, mortality, and healthcare costs, the majority of 
which arise from those with severe disease. Omalizumab is a monoclonal antibody to immunoglobulin E (IgE) that has been developed 
for the treatment of severe persistent allergic (IgE mediated) asthma.
Aims: The aim of this review is to evaluate the available clinical evidence on omalizumab to determine the role it has to play in the 
treatment of persistent allergic asthma.
Evidence review: There is clear evidence to show that omalizumab is effective in reducing the rate of asthma exacerbations, inhaled 
corticosteroid dose, and the need for rescue medication in patients with allergic asthma. Clinical data indicate beneficial effects on 
patient-reported symptoms and perceived quality of life, as well as a reduction in unscheduled healthcare visits. There is little evidence to 
suggest omalizumab may enhance lung function or reduce the requirement for oral corticosteroids. Omalizumab has a favorable safety 
profile, although anaphylaxis has occurred. A study in children showed similar results to those achieved in adults and adolescents, with 
fewer asthma exacerbations and school days missed. Omalizumab may be cost effective in patients when used as add-on therapy to 
inhaled corticosteroids and long-acting beta2 agonists (LABA).
Place in therapy: Omalizumab is an effective add-on therapy to inhaled corticosteroids and LABAs in adults and adolescents with severe 
persistent allergic asthma. Currently there is insufficient evidence to support the use of omalizumab in children.
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Core evidence place in therapy summary for omalizumab in the treatment of allergic asthma
Outcome measure Evidence Implications
Patient-oriented evidence
Reduction in inhaled corticosteroid medication Clear Effective inhaled corticosteroid sparing agent 
Reduction in asthma exacerbations Clear Fewer exacerbations when used as add-on therapy to inhaled 
corticosteroids with or without long-acting beta2 agonists
Reduction in rescue medication Clear Effective in decreasing the need for rescue medication
Reduction in emergency room visits and hospitalization Clear Fewer unscheduled healthcare visits when compared with placebo
Improvement in asthma symptoms Substantial Significant reduction from baseline symptoms in adults but not shown  
in children
Reduction in oral corticosteroid use No evidence Evidence required
Disease-oriented evidence
Improvement in lung function Limited May improve FEV1 and morning PEF
Improvement in asthma-related quality of life score Substantial Beneficial effects on patient perceived quality of life
Economic evidence
Cost effective as add-on therapy to inhaled 
corticosteroids and long-acting beta2 agonists in severe 
persistent allergic asthma
Limited £38 900 per QALY gained 
May be cost effective in those with an elevated risk of asthma- 
related mortality
FEV1, forced expiratory volume in 1 s; PEF, peak expiratory flow; QALY, quality-adjusted life-year.Omalizumab | place in therapy
Scope, aims, and objectives
Omalizumab  (Xolair®,  Novartis  Pharma  AG)  is  a  recombinant 
DNA-derived humanized immunoglobulin G (IgG) 1k monoclonal 
antibody that selectively binds to human immunoglobulin E (IgE) 
and has been developed for the treatment of allergic asthma. It 
binds to IgE at the high affinity IgE receptor-binding site, forming 
immune complexes with free IgE (Presta et al. 1993). This binding 
inhibits interaction of IgE with IgE receptors on the surface of 
mast cells, basophils, and other cell types, preventing the release 
of inflammatory mediators that occur in allergic asthma. 
The purpose of this article is to review the evidence behind the 
use of omalizumab in the treatment of allergic asthma, including 
its effects on outcomes such as reduction of corticosteroid use, 
asthma exacerbation rates, and lung function.
Methods
The  English  language  literature  was  reviewed  for  appropriate 
articles relating to omalizumab for the treatment of asthma. The 
following databases were searched during July 2007 using the 
search terms “(Omalizumab OR Xolair) AND asthma”:
•   PubMed, http://www.ncbi.nlm.nih.gov/sites/entrez?db= 
pubmed 
•   Cochrane Database of Systematic Reviews (CDSR),  
http://www.cochrane.org/index0.htm 
•   National  Institute  for  Health  and  Clinical  Excellence  (NICE), 
www.nice.org.uk 
•   National Guideline Clearing House, www.guideline.gov 
Only studies in patients with asthma were included and no date 
limitations were placed on the search.
Several guidelines relating to asthma management were identified, 
however, only two recent guidelines applicable on a worldwide 
scale were considered relevant to this review. 
Two hundred and eighteen full papers were identified in the initial 
search. Records were manually reviewed and a total of 173 were 
excluded: nonsystematic reviews (n=129), in-vitro studies (n=3), 
letters and editorials (n=7), and articles that mentioned omalizumab 
but did not investigate its clinical use in asthma (n=34). Review of 
the reference lists of systematic review and meta analysis studies 
yielded  six  additional  studies.  One  economic  reference  was 
published after the initial literature search was performed and 
was included in this review (NICE 2007). A total of 47 abstracts 
were retrieved and were also manually reviewed. Forty-two were 
excluded: duplicate publications of data presented in full papers 
(n=34), in-vitro studies (n=1), or studies that did not investigate 
the clinical use of omalizumab in asthma (n=7) (Table 1).
Disease overview
Asthma  is  a  chronic  inflammatory  disorder  of  the  airways 
characterized by airflow limitation, airway hyperresponsiveness, 
and inflammation of the bronchi. To establish a diagnosis there 
must be the presence of episodic symptoms of airflow obstruction, 
evidence of at least partially reversible airflow obstruction, and 
the exclusion of alternative diagnoses (Anon 1992). The World 
Health  Organization  (WHO)  estimates  that  300  million  people 
suffer from asthma and 250 000 people die annually worldwide 
from asthma (GINA 2006a). Asthma is a significant burden, not 
only in terms of healthcare costs but also from lost productivity 
and reduced participation in family life. The economic cost of 
asthma  is  considerable  comprising  both  direct  medical  costs 
such as hospital admissions and the cost of medication, and 
indirect medical costs such as time lost from work and premature 
death.  The  number  of  disability-adjusted  life  years  (DALYs) 
lost due to asthma worldwide has been estimated to be about   
15 million per year. Worldwide asthma accounts for around 1% 
of all DALYs lost, reflecting the high prevalence and severity of 
asthma (Masoli et al. 2004).
There are 10.1 million people in the British Isles who suffer from 
asthma with a mean prevalence of clinical asthma estimated at 
16.1%, which is among the highest rates of asthma in the world 
(Masoli et al. 2004). The incidence of asthma diagnosed over the 
last few decades has markedly increased, such that it is now 
about five times higher than it was 25 years ago. The total cost 
of asthma in the British Isles has been estimated to be about   
£2.5 billion, including a cost of around £900 million to the public 
health service (Masoli et al. 2004). It is estimated that 50% of all 
annual healthcare costs for asthma come from the most severe 
20% of the asthmatic population. About 20 million working days 
are lost to asthma each year (Masoli et al. 2004).
Pathophysiology
Airway  inflammation  involves  cellular  infiltration  of  eosinophils 
and  lymphocytes;  changes  in  resident  cells  including  mast 
cell sensitization and smooth muscle hypertrophy; and airway 
wall changes with collagen deposition and airway remodeling. 
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Number of records
Category Full papers Abstracts
Initial search 218 47
records excluded 173 42
records included 45 5
Additional studies identifieda 7 0
Total records included 52 5
Level 1 clinical evidence 8 0
Level 2 clinical evidence  31 4
Level ≥3 clinical evidence 8 1
trials other than RCT 3 1
case reports 5 0
Economic evidence 5 0
aAdditional studies identified equals any relevant study that was identified from a source 
other than the main searches, e.g. a reference list. For definition of levels of evidence, see 
inside back cover or website (http://www.coremedicalpublishing.com).
RCT, randomized controlled trial.
   Table 1 |   Evidence base included in the reviewOmalizumab | place in therapy
A  network  of  cytokines  and  growth  factors  orchestrates  this 
bronchial inflammation resulting in the airway obstruction and 
bronchial  hyperresponsiveness  that  characterizes  asthma 
(Drazen 2007).
IgE plays a central role in allergic asthma. Allergic sensitization 
results from the formation of specific IgE in response to common 
inhaled  allergens  such  as  pollen  and  house  dust  mites.  IgE 
formation is stimulated by the release of interleukin 4 (IL-4) and 
interleukin 13 (IL-13) produced by several cell types including 
a subset of T-helper lymphocytes prevalent in atopy called Th2 
cells  (Guachat  et  al.  1990;  de  Vries  et  al.  1999).  Specific  IgE 
released  from  B  lymphocytes  circulates  and  binds  to  specific 
high-affinity receptors (Fc-epilson-RI) on the surface of mast cells 
and basophils. IgE is activated by the cross bridging of protein 
allergens  resulting  in  the  release  of  histamine  and  increased 
synthesis  of  inflammatory  mediators  such  as  prostaglandins, 
causing  bronchoconstriction  and  plasma  exudate  in  allergic 
asthmatic patients (Turner & Kinet 1999). In order to inhibit this 
mechanism  it  is  essential  to  effectively  eradicate  circulating 
IgE,  as  there  are  10 000  to  1 000 000  Fc-epsilon-RI  on  mast   
cells  and  basophils  and  nearly  all  are  occupied  by  IgE.  Only   
2000  IgE  molecules  are  needed  for  half  maximal  release  of 
histamine from basophils (Barnes 2007; MacGlashan 1993).
Current therapy options
The mainstay of pharmacologic treatment of asthma involves the 
use of inhaled bronchodilators and corticosteroids with the titration 
of the dose and the introduction of additional therapies occurring 
in a stepwise fashion. The aim of pharmacologic management 
of asthma is to control symptoms, prevent exacerbations, and 
achieve the best possible pulmonary function with minimal side 
effects. In the UK, the British Thoracic Society (BTS) and Scottish 
Intercollegiate Guidelines Network (SIGN) have produced a set 
of stepwise guidelines using evidence-based methodology that 
aim to eradicate symptoms as quickly as possible and optimize 
peak flow (BTS, SIGN 2007). These guidelines have become the 
cornerstone of asthma treatment within the NHS. On a worldwide 
scale  the  Global  Initiative  for  Asthma  (GINA)  has  produced  a 
global strategy for asthma management and prevention (GINA 
2006a). They too have incorporated a management framework 
based on clinical control that uses a stepwise approach. Both 
sets  of  guidelines  are  very  similar  and  aim  to  achieve  and 
maintain asthma control by stepping up treatment as necessary 
and stepping down when control is good (see Figs. 1 and 2).
Unmet needs
Approximately 5–10% of asthmatic patients remain symptomatic 
despite treatment at step 4 or step 5 of the BTS/SIGN guidelines 
(BTS, SIGN 2007), and are referred to as having “difficult asthma”. 
Multidisciplinary  evaluation  protocols  have  demonstrated 
that  approximately  50%  of  this  difficult  to  control  population 
have  identifiable  factors  contributing  to  poor  control,  such  as 
nonadherence,  alternative/additional  diagnoses  or  contributing 
comorbidities  such  as  nasal  disease,  or  psychosocial  factors 
(Heaney et al. 2003; Robinson et al. 2003). The remaining patients 
have refractory asthma or therapy-resistant disease, where new 
therapeutic options are required.
The American Thoracic Society (ATS 2000) uses major and minor 
diagnostic characteristics to define refractory asthma. The patient 
should have symptoms of mild-to-moderate persistent asthma 
despite  treatment  with  continuous  or  near  continuous  (≥50% 
of  the  year)  oral  corticosteroids  or  high-dose  inhaled  steroids 
equivalent to >1260 mcg/day beclomethasone dipropionate. They 
must also display two minor characteristics from the following 
list: requirement for additional long-acting beta2 agonists (LABA), 
theophylline,  or  leukotriene  anatagonist;  symptoms  requiring 
short-acting beta2 agonist on a daily or near-daily basis; persistent 
airway  obstruction  [forced  expiratory  volume  in  1  s  (FEV1)   
<80% predicted; diurnal variability >20%]; one or more urgent 
care visits for asthma per year; three or more oral steroid bursts 
per year; prompt deterioration on reducing inhaled steroid dose; 
or a near-fatal asthma event in the past. Other conditions must 
have been excluded, exacerbation factors treated, and patients 
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Step 1 Mild intermittent asthma
Inhaled short-acting beta2 agonists as required
Step 2 Regular preventer therapy
Add inhaled steroid 200–800 mcg/daya
400 mcg is an appropriate starting dose for many patients
Start at the dose of inhaled steroid appropriate to severity  
of disease
Step 3 Add-on therapy
Add inhaled LABA
Assess control of asthma:
• good response to LABA – continue LABA
•   benefit from LABA but control still inadequate – continue 
LABA and increase inhaled steroid dose to 800 mcg/daya
•   no response to LABA – stop LABA and increase inhaled 
steroid to 800 mcg/daya
•   if control still inadequate, institute trial of other therapies,  
e.g. leukotriene receptor antagonist or SR theophylline
Step 4 Persistent poor control
Increase inhaled steroid up to 2000 mcg/daya
Add a fourth drug e.g. leukotriene receptor antagonist, SR 
theophylline, beta2 agonist tablet
Step 5 Continuous or frequent use of oral steroids
Use daily steroid tablet in the lowest dose providing  
adequate control
Maintain high dose inhaled steroid at 2000 mcg/daya
Consider other treatments to minimize the use of  
steroid tablets
Refer patient for specialist care
Fig. 1 | BTS/SIGN Guidelines: summary of stepwise 
management of asthma in adults (BTS, SIGN 2007). Patients 
should start treatment at the step most appropriate to the initial 
severity of their asthma. 
aBeclomethasone dose or equivalent. 
BTS/SIGN, British Thoracic Society/Scottish Intercollegiate 
Guidelines Network; LABA, long-acting beta2 agonist; SR, 
sustained release.Omalizumab | place in therapy
felt to be generally adherent with their medication for this definition 
of refractory asthma. 
This group of patients is at a high risk of asthma death, account 
for a substantial proportion of the total cost of asthma, and have 
significantly impaired quality of life. Omalizumab and other novel 
therapies may have a potential role in this group of subjects.      
Clinical evidence with omalizumab
Effect on IgE levels
Aerosolizing  omalizumab  is  an  ineffective  method  for  the 
administration of this agent, principally as it does not reduce serum 
free IgE levels regardless of low-dose (1 mg) or high-dose (10 mg) 
therapy. It was no more effective than placebo in improving lung 
function and reducing a bronchial allergen challenge (Fahy et al. 
1999).  Subcutaneous  and  intravenous  delivery  of  omalizumab 
however causes significant reductions in serum free IgE, ranging 
from 89% to 99% irrespective of different dosing regimens within 
different trials (Walker et al. 2006). One study showed a rapid 
and sustained fall in free serum IgE of 96% following 100 mg 
of intravenous omalizumab, with a mean recovery of 50% by   
39  days  (Corne  et  al.  1997).  Doses  ranging  from  0.0005  to 
0.14 mg/kg subcutaneously or 0.05 to 1.0 mg/kg intravenously 
decrease free serum IgE levels in plasma in a dose-dependent 
fashion in both adults and children (Barnes 2000; Fahy 2000). 
Comparison of intravenous administration of omalizumab with 
placebo  in  patients  with  mild  asthma  not  receiving  inhaled 
corticosteroids resulted in a significant decrease in serum free 
IgE levels from baseline concentrations (P<0.00001 and P<0.001 
in two separate studies) (Boulet et al. 1997; Fahy et al. 1997). No 
change in serum free IgE was reported in the placebo groups. 
Intravenous omalizumab also caused a significant improvement 
in patients’ response to a methacholine challenge, which was not 
observed in the control group (Boulet et al. 1997). No significant 
difference  was  detected  in  the  use  of  rescue  medication  or 
improvements in lung function.
Subcutaneous  omalizumab  also  results  in  significantly  lower 
free IgE levels compared with placebo. No significant difference 
occurred in terms of change in FEV1 or response to a methacholine 
challenge  between  omalizumab  and  placebo  in  patients  with 
mild  asthma  and  not  on  inhaled  corticosteroids  (van  Rensen 
et al. 2005; Prieto et al. 2006). However, one study reported a 
significant difference in the allergen-induced late phase response 
in patients treated with omalizumab (van Rensen et al. 2005).
Moderate-to-severe asthma
The effects of omalizumab on asthma exacerbation and steroid 
use are summarized in Tables 2 and 3.
Busse  et  al.  (2001)  performed  a  double-blind,  placebo-
controlled trial in 525 patients with moderate-to-severe allergic 
asthma requiring daily inhaled corticosteroids (beclomethasone 
dipropionate). There was a 4–6 week run in, in which patients 
were  changed  from  their  prescribed  inhaled  corticosteroids 
to  an  equivalent  dose  of  beclomethasone  dipropionate  with 
stabilization. Following this, patients were randomized to receive 
placebo or subcutaneous omalizumab 0.016 mg/kg IgE (IU/mL) 
every 4 weeks. A steroid stable phase of 16 weeks was followed 
by  a  12-week  steroid  reduction  phase,  where  the  inhaled 
corticosteroid was tapered to the lowest dose. During the stable 
phase, significantly fewer omalizumab recipients than placebo 
experienced one or more exacerbations (14.6% versus 23.3%, 
respectively; P=0.009), and there were significantly fewer asthma 
exacerbations  per  patient  (0.28  versus  0.54;  P=0.006).  These 
outcomes  also  occurred  during  the  steroid  reduction  phase 
(21.3% versus 32.3%, P=0.004, and 0.39 versus 0.66, P=0.003, 
respectively).  Steroid  reduction  was  significantly  greater  with 
omalizumab treatment than with placebo (median 75% versus 
50%; P<0.001). The number of patients receiving omalizumab 
who were able to withdraw from inhaled steroid use was twice that 
of those in the placebo group (39.6% versus 19.1%; P<0.001). 
Omalizumab also significantly improved daily asthma scores and 
reduced rescue medication use in comparison with placebo.
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Level of control Treatment action
Controlled Maintain and find lowest controlling step
Partly controlled Consider stepping up to gain control
Uncontrolled Step up until controlled
Exacarbation Treat as exacerbation
Treatment stepsa
Asthma education
Environmental control
Step 1 As needed rapid-acting beta2 agonists
Step 2 As needed rapid-acting beta2 agonists + one from 
the following:
• low-dose inhaled ICS
• leukotriene modifierb
Step 3 As needed rapid-acting beta2 agonists + one from 
the following:
• low-dose ICS and LABA
• medium- or high-dose ICS
• low-dose ICS + leukotriene modifierb
• low-dose ICS + SR theophylline
Step 4 Add one or more from the following:
• medium- or high-dose ICS + LABA
• leukotriene modifierb
• SR theophylline
Step 5 Add one or more from the following:
• oral glucocorticosteroid (lowest dose)
• anti-IgE treatment
Fig. 2 | GINA Guidelines: management approach based on 
control for children older than 5 years, adolescents, and adults 
(GINA 2006a).  
aFor steps 2, 3, and 4 the preferred controller is the first option. 
bReceptor antagonist or synthesis inhibitors. 
GINA, Global Initiative for Asthma; IgE, immunoglobulin; ICS, 
inhaled glucocorticosteroid; LABA, long-acting beta2 agonist; 
SR, sustained release.Omalizumab | place in therapy
Solèr  et  al.  (2001),  conducted  a  similar  investigation  in   
546  allergic  asthmatics,  aged  12–76  years  who  were 
symptomatic despite inhaled corticosteroids (500–1200 mcg of 
beclomethasone dipropionate). The same methods as the Busse 
et al. (2001) study were used, with a 16-week steroid stable phase 
and a 12-week steroid reduction phase. The omalizumab group, 
again, had significantly fewer asthma exacerbations per patient 
and fewer experienced one or more exacerbations in the steroid 
stable phase compared with the placebo group (0.28 versus 0.66, 
P<0.001, and 12.8% versus 30.5%, P<0.001, respectively). This 
pattern  continued  in  the  steroid  reduction  phase  (0.36  versus 
0.75, P<0.001, and 15.7% versus 29.8%, P<0.001, respectively). 
The proportion of patients who were able to reduce the dose of 
steroids was significantly higher in the omalizumab group than 
in the placebo group (P<0.001). Furthermore, 43% of patients 
on omalizumab withdrew inhaled steroids completely compared 
with  19%  on  placebo.  Significant  improvements  in  symptom 
scores and use of rescue medication occurred in the omalizumab 
group compared with the placebo group despite the more marked 
reduction in dosage of beclomethasone dipropionate.
Extensions to the original investigations by Solèr et al. (2001) 
and Busse et al. (2001) assessed long-term control in patients 
with moderate-to-severe asthma receiving omalizumab therapy 
(Buhl et al. 2002b; Lanier et al. 2003). Participants could continue 
into a 24-week double-blind extension phase and be maintained 
on  their  randomized  treatment  and  the  lowest  sustainable 
dose of inhaled corticosteroid. The use of concomitant asthma 
medication  was  permitted,  and  investigators  could  adjust  the 
beclomethasone dipropionate dose or switch to another inhaled 
corticosteroid if considered necessary. Findings indicated that 
fewer numbers of exacerbations occurred in omalizumab-treated 
patients despite a sustained significant reduction in their use of 
inhaled corticosteroids when compared with the placebo control 
group  [P=0.023  (Lanier  et  al.  2003)  and  P<0.001  (Buhl  et  al. 
2002b)], indicating that omalizumab is effective in the long-term 
control of allergic asthma.
Ayres et al. (2004) performed an open-label trial in patients with 
poorly controlled moderate-to-severe allergic asthma in which the 
addition of omalizumab to best standard care caused a reduction 
in the number of clinically significant asthma exacerbations per 
patient-year  (1.12  versus  2.86;  P<0.001)  compared  with  best 
standard  care  alone.  This  evidence  highlights  the  potential 
benefit of using omalizumab as add-on therapy in patients with 
moderate-to-severe asthma. 
Severe allergic asthma
Holgate et al. (2004) investigated the effect of omalizumab on 
patients  with  severe  allergic  asthma  using  high-dose  inhaled 
fluticasone  propionate.  This  study  used  similar  methods  to 
those of Solèr et al. (2001) and Busse et al. (2001); however the 
steroid reduction phase was 4 weeks longer, lasting 16 weeks. 
Median reductions in fluticasone dose were significantly greater 
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Asthma severity Study Steroid use Exacerbations (mean per patient)
Placebo Omalizumab P value
Moderate/severe Busse et al. 2001 Steroid stable 0.54 0.28 0.006
Steroid reduction 0.66 0.39 0.003
Solèr et al. 2001 Steroid stable 0.66 0.28 <0.001
Steroid reduction 0.75 0.36 <0.001
Vignola et al. 2004 (asthma and allergic rhinitis) - 0.25 0.40 0.02
Milgrom et al. 2001 (childhood asthma) Steroid stable 0.40 0.30 0.093
Steroid reduction 0.72 0.42 <0.001
Severe Holgate et al. 2004 Steroid stable 0.23 0.15 -
Steroid reduction 0.34 0.19 -
Humbert et al. 2005 -  0.91 0.68 0.42a
aStatistically significant following post-hoc adjustment for baseline exacerbation history.
   Table 2 |   Effects of omalizumab on asthma exacerbations in placebo-controlled trials conducted in patients with  
allergic asthma
Asthma severity Study Patients (%) reducing inhaled steroid dose by ≥50% Patients (%) withdrawing inhaled steroids
Placebo Omalizumab P value Placebo Omalizumab P value
Moderate/severe Busse et al. 2001 55 72 <0.001 19 40 0.003
Solèr et al. 2001 55 79 - 19 43 -
Milgrom et al. 2001 66.7 100.0 0.001 39.0 55.0 0.004
Severe Holgate et al. 2004 51 74 0.001 15 21 0.198
   Table 3 |   Inhaled corticosteroid reduction with omalizumab in placebo-controlled trials in allergic asthmaOmalizumab | place in therapy
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with omalizumab than with placebo (60% versus 50%; P=0.003). 
Omalizumab  reduced  rescue  medication,  improved  asthma 
symptoms,  and  asthma-related  quality  of  life  compared  with 
placebo through both phases of the study. This indicates that the 
effect of omalizumab translates to patients requiring high-dose 
inhaled corticosteroids and remains constant regardless of which 
type of inhaled corticosteroid patients are treated with.
The  INNOVATE  study  (Humbert  et  al.  2005)  examined  the 
impact of omalizumab as add-on therapy in patients with severe 
persistent  asthma  inadequately  controlled  despite  high-dose 
inhaled corticosteroids and LABAs (GINA 2002 step 4 treatment). 
This was a multicenter, randomized, placebo-controlled, double-
blind  study  comprising  a  7-day  screening  period  to  evaluate 
eligibility,  an  8-week  run-in  phase,  a  28-week  drug  add-on 
treatment  phase,  and  a  16-week  follow-up  phase.  Results 
from 419 patients showed the addition of omalizumab reduced 
the  severe  exacerbation  rate  (0.24  versus  0.48;  P=0.002)  and 
emergency visit rate (0.24 versus 0.43; P=0.038). It also improved 
the clinically significant exacerbation rate (i.e. requiring systemic 
corticosteroids) during the 28-week treatment phase, however 
this had to be adjusted for an observed relevant imbalance in 
history of clinically significant asthma exacerbations to become 
statistically  significant  (0.68  versus  0.91;  P=0.042).  Asthma-
related quality of life, morning peak expiratory flow (PEF), and 
asthma  symptom  scores  were  also  significantly  improved  in 
omalizumab recipients.
A  meta  analysis  by  Holgate  et  al.  (2001)  of  three  phase  III 
trials (Busse et al. 2001; Solèr et al. 2001; Holgate et al. 2004) 
was  conducted  to  determine  the  efficacy  of  omalizumab  in  a 
subgroup  of  patients  at  high-risk  of  serious  asthma-related 
morbidity and mortality. High-risk patients were defined as those 
who  had  visited  an  emergency  room,  experienced  overnight 
hospitalization, or received treatment in an intensive care unit 
during the last year, as well as those who had been intubated 
at  some  time  prior  to  screening.  This  definition  identified   
254 high-risk patients from the total 1412 participants. The primary 
outcome measure was the annualized rate of significant asthma 
exacerbation episodes, those requiring a doubling of baseline 
inhaled corticosteroid dose, during the steroid stable phase. This 
meta  analysis  demonstrated  that  omalizumab  reduced  mean 
rates  of  significant  exacerbation  episode  per  patient-year  in 
this high-risk group compared with placebo (0.69 versus 1.56; 
P=0.007). In 93 patients with a history of hospitalization in the last 
year, fewer on omalizumab were rehospitalized during the study 
period (4.5% versus 12.0%). Patients treated with omalizumab 
also showed significantly greater improvements from baseline in 
PEF (P=0.026), overall asthma-related quality of life (P=0.042), 
mean  nocturnal  (P=0.007)  and  mean  total  (P=0.011)  asthma 
symptom scores compared with placebo.
Emergency room visits
Corren et al. (2003) analyzed the effects of omalizumab on serious 
asthma exacerbations in patients requiring treatment with inhaled 
corticosteroids for allergic asthma. They used data collected in 
three phase III studies: two in adults and adolescents (Busse et 
al. 2001; Solèr et al. 2001) and one trial involving children aged 
6–12 years (Milgrom et al. 2001). 
They  found  that  the  rate  of  unscheduled  asthma-related 
outpatient  visits  was  significantly  lower  per  100  patient-years 
in omalizumab-treated patients compared with those receiving 
placebo  (21.3  versus  35.5,  rate  ratio=0.60;  P<0.01).  There 
was  also  a  statistically  significant  reduction  in  asthma-related 
emergency room visits per 100 patient-years (1.8 versus 3.8, rate 
ratio=0.47; P=0.05). Hospitalizations due to asthma were 92% 
lower in omalizumab-treated patients compared with the placebo 
group (P<0.01).
In addition, pooled analysis by Bousquet et al. (2005) from seven 
clinical trials revealed that omalizumab significantly reduced the 
rate of total emergency visits by 47% (P<0.001 versus control) in 
patients with severe persistent asthma. This meta analysis also 
demonstrated a reduction in the rate of asthma exacerbations by 
38% (P<0.0001 versus control). 
These results signify that treatment with omalizumab may confer 
benefits in quality of life, as well as economic advantages by 
reducing the amount of costly unscheduled healthcare.
Quality of life
Moderate-to-severe asthma has a substantial impact on patients’ 
quality of life. Niebauer et al. (2006) summarized the asthma-
related quality of life outcomes associated with omalizumab in 
a meta analysis of five published clinical trials and extensions 
(Busse et al. 2001; Milgrom et al. 2001; Solèr et al. 2001; Buhl et 
al. 2002a; Lemanske et al. 2002; Finn et al. 2003; Holgate et al. 
2004; Vignola et al. 2004), as well as unpublished clinical study 
reports from the manufacturer. The Juniper Asthma Quality of 
Life Questionnaire was used to measure asthma-related quality 
of life. 
Omalizumab treatment resulted in a significant improvement of 
asthma-related quality of life score compared with placebo in the 
steroid reduction phase of each study (P<0.05). Meta analysis 
illustrated this trend extending through the steroid stabilization 
(P=0.003) and extension phases (P=0.003), however, statistical 
significance was not achieved for each individual trial during these 
phases. Meta analysis also indicated a 1.6- to 2-fold increase 
in moderate (≥1 point) (P<0.001) and 1.8- to 2.1-fold increase in 
large (≥1.5 point) (P<0.001) improvements in overall quality of life 
scores in omalizumab-treated patients compared with placebo 
during  both  steroid  stabilization  and  steroid  reduction.  This 
analysis reveals the significant improvements in quality of life in 
patients  with  moderate-to-severe  asthma  through  treatment   
with omalizumab. 
Chipps et al. (2006) emphasized the effect of add-on omalizumab 
on asthma-related quality of life with a pooled analysis of six 
controlled clinical trials comprising 2548 patients (Busse et al. 
2001; Solèr et al. 2001; Ayres et al. 2004; Holgate et al. 2004; 
Vignola et al. 2004; Humbert et al. 2005) (Table 4). They also found 
that omalizumab produced significantly greater improvements in 
Juniper Asthma Quality of Life Questionnaire total score (P<0.001) 
and  significantly  more  clinically  meaningful  improvements   Omalizumab | place in therapy
(≥0.5 point score increase) (P<0.001) compared with patients in 
the control groups.
Unpublished  data  collected  by  Holgate  et  al.  (2004)  and 
analyzed by Walker et al. (2006) reiterated the clinically relevant 
improvements in quality of life in patients with severe asthma 
treated  with  omalizumab  compared  with  placebo.  More 
patients had a >0.5 change in Juniper score with omalizumab 
compared with placebo (57.5% versus 38.6%; P<0.05). Further 
meta analysis also revealed that patients in two studies treated 
with  subcutaneous  omalizumab  were  more  likely  than  their 
counterparts in the placebo group to rate asthma control as good 
or excellent during the steroid stable phase (P<0.001). This trend 
continued in the steroid reduction phase [number needed to treat 
(NNT), 5].
Symptom score
Asthma  symptom  scores  were  calculated  using  a  0–4  point 
scale for daytime and nocturnal symptoms and 0–1 point scale 
for symptoms on waking, as rated by patients, with a maximum 
score of 9. Analysis of these scores in three studies (Busse et 
al. 2001; Solèr et al. 2001; Holgate et al. 2004) by Walker et al. 
(2006),  demonstrated  that  omalizumab  therapy  significantly 
decreased  end  of  treatment  asthma  symptom  scores  during 
the  stable  steroid  phase  in  patients  with  moderate-to-severe 
asthma. However this represented a reduction of just 10% from   
baseline values. 
Significant  reductions  from  baseline  symptom  scores  were 
demonstrated by Humbert et al. (2005) and Vignola et al. (2004) 
in favor of omalizumab during the steroid stable phase (P=0.023 
and P=0.039, respectively). This reduction did not occur in the 
pediatric  population  (Milgrom  et  al.  2001).  During  the  steroid 
reduction phase in patients with moderate-to-severe asthma only 
Busse et al. (2001) described a significantly greater mean change 
in symptom scores from baseline with omalizumab compared 
with placebo.
Lung function
The evidence for the effect of omalizumab on lung function is 
conflicting. In adolescent and adult patients with moderate-to-
severe  asthma,  two  studies  have  shown  small  but  significant 
improvements from baseline FEV1 of 2.8% (P=0.043) (Humbert 
et al. 2005) and 73 mL (P=0.032) (Vignola et al. 2004). However, 
the meta analysis by Walker et al. (2006) reported no significant 
difference  in  end  of  treatment  FEV1  and  morning  PEF  with 
subcutaneous omalizumab compared with placebo. A small but 
significant increase in morning PEF has been reported in patients 
treated  with  intravenous  omalizumab  compared  with  placebo 
(30.7 versus 11.3 L/min; P=0.007) (Milgrom et al. 1999). There 
was no difference in FEV1 between the two groups.
The  benefit  of  improved  lung  function  in  asthma  on  clinically 
relevant findings is unclear, with a poor association between lung 
function and both health-related quality of life (Wijnhoven et al. 
2001)  and  reduced  hospital  admissions  (Qureshi  et  al.  1998). 
The inconsistent effects of omalizumab on lung function despite 
improved asthma outcomes emphasize the uncertain relationship 
between asthma severity and lung function.
Use in children
Milgrom  et  al.  (2001)  evaluated  the  impact  of  omalizumab 
on  the  treatment  of  childhood  asthma  in  334  children  aged   
6–12  years  with  moderate  to  severe  allergic  asthma  requiring 
inhaled corticosteroids (beclomethasone dipropionate). The study 
design and dosing was similar to that used in the studies of Busse 
et al. (2001) and Solèr et al. (2001). Children receiving omalizumab 
were able to decrease their beclomethasone dipropionate dose 
by  a  greater  amount  (median  reduction  100%  versus  66.7%; 
P=0.001),  with  a  higher  percentage  able  to  withdraw  inhaled 
corticosteroids  completely,  compared  with  the  placebo  group 
(55% versus 39%; P=0.004). Children receiving omalizumab also 
had significantly fewer asthma exacerbations during the steroid 
reduction  phase  (18.2%  versus  38.5%;  P<0.001),  significantly 
fewer  urgent  unscheduled  outpatient  physician  visits  (12.9% 
versus  30.3%;  P=0.001),  fewer  missed  school  days  (0.65   
versus 1.21 days; P=0.04), and fewer two or three consecutive 
night  awakenings  requiring  rescue  medication  (11.6%  versus 
21.1%; P=0.002). There was no significant difference between 
asthma  symptom  scores  or  lung  function  measurements  in   
each group. 
The  use  of  monthly  injections  of  omalizumab  may  present  a 
compliance problem in pediatric patients and this study reported 
a small number of withdrawals due to pain and fear of injection 
(Milgrom et al. 2001). This compliance issue may lead to an extra 
dilemma in the treatment of children. However, it is worth noting 
that over 200 children did tolerate treatment.
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Asthma severity Study Change from baseline in total AQLA score, least square mean (n)
Placebo Omalizumab P value
Moderate/severe Busse et al. 2001 0.61 (246) 0.93 (256) <0.001
Solèr et al. 2001 0.64 (235) 1.02 (244) <0.001
Vignola et al. 2004 1.12 (192) 1.39 (208) 0.01
Severe Holgate et al. 2004 0.18 (152) 0.46 (158) 0.011
Humbert et al. 2005 0.49 (205) 0.94 (204) <0.001
   Table 4 |   Effect of omalizumab on Juniper Asthma Quality of Life Questionnaire (AQLQ) compared with placebo in allergic 
asthma (reproduced from Chipps et al. 2006, with permission)Omalizumab | place in therapy
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Safety and tolerability
Omalizumab has been extensively evaluated for adverse events. 
Deniz and Gupta (2005) performed a pooled analysis of 12 clinical 
trials involving 5328 patients with moderate-to-severe persistent 
asthma. They reported the use of omalizumab to have a similar 
safety  profile  to  that  of  the  control  group,  with  no  significant 
differences between groups. Walker et al. (2006) analyzed safety 
data and revealed a significant increase in injection-site reactions 
in patients treated with subcutaneous omalizumab and inhaled 
corticosteroid compared with placebo and inhaled corticosteroid 
[odds ratio=2, 95% confidence interval (CI) 1.37, 2.92, control 
event rate=5.5%], which they calculated to equate to an NNT 
of 21. They described no difference in the number of patients 
with  urticaria,  headache,  adverse  events,  or  withdrawal  due 
to adverse events. However, the exact number of studies and 
patients involved in this analysis was not stated. 
Anaphylaxis occurred in three patients who received omalizumab 
during  clinical  trials,  representing  approximately  1%  of  all 
patients  receiving  the  drug.  In  postmarketing  surveillance, 
the frequency of anaphylaxis was estimated to occur in 0.2% 
of  patients  treated  with  omalizumab,  based  on  an  estimated   
57 300  patients  treated  with  omalizumab  (Anon  2007). 
Anaphylactic reactions have included urticaria, bronchospasm, 
syncope,  hypotension,  and/or  angioedema  of  the  throat  and 
tongue. This led to the US FDA releasing an alert in February 
2007, updated in July 2007, regarding the risk of anaphylaxis   
in patients receiving omalizumab (FDA 2007). The FDA advises 
that omalizumab should only be administered in a healthcare 
setting under direct medical supervision and that patients are 
observed for an appropriate length of time after administration. 
Malignant neoplasms have been reported in 25 of 5015 (0.5%) 
omalizumab-treated  patients  compared  with  five  of  2854 
(0.2%) control patients in completed clinical trials (Fernandez et 
al. 2005). A comparison of cancer rates with the US National 
Institutes  of  Health  (NIH)  SEER  database  found  that  the 
standardized incidence ratio of observed to expected number 
of events with omalizumab was similar to that expected in the 
general  population,  and  in  the  control  group  it  was  one-third   
of  that  expected  (95%  CI,  0.55,  1.62  versus  0.04,  1.11).  No   
cases  of  malignant  neoplasm  were  considered  drug-
related  by  a  panel  of  independent  oncologists,  blinded  to   
treatment assignment (Fernandez et al. 2005).
It has been postulated that IgE initiates an antibody dependent 
cell-mediated  cytotoxic  response  against  helminthic  parasites 
(Winter  et  al.  2000).  This  has  lead  to  concern  that  treatment 
with omalizumab may adversely affect immunity and increase 
susceptibility of helminth infection. Cruz et al. (2007) conducted 
a  randomized,  double-blind,  placebo-controlled  trial  in   
137  patients  at  high  risk  of  geohelminth  infection.  Although 
there  was  an  increased  frequency  geohelminth  infection  in   
omalizumab recipients (50% versus 41%), it was not statistically 
significant  (OR  1.47,  95%  CI  0.74,  2.95).  This  suggests  that 
omalizumab  does  not  cause  increased  susceptibility  to   
helminthic parasites.
Safety in children
Berger et al. (2003) evaluated the long-term effects of omalizumab 
in children by performing a 24-week extension to the study by 
Milgrom et al. (2001), and completing a safety analysis of the 
core  study.  All  309  children  received  open-label  omalizumab 
in addition to other asthma medications during the extension 
phase.  The  incidence  of  adverse  events  in  patients  treated 
with omalizumab for 52 weeks was similar to those treated for 
28 weeks in the core trial, which was generally comparable to 
placebo.  Urticaria  was  reported  in  11  patients  (4.9%),  which 
resolved spontaneously or with antihistamine, apart from severe 
urticaria in one patient that necessitated omalizumab therapy 
discontinuation.  No  anaphylactic  reactions  or  adverse  events 
suggestive  of  serum  sickness  or  immune  complex  formation 
occurred,  and  antiomalizumab  antibodies  were  not  detected 
in  any  child.  The  most  frequently  reported  adverse  events 
were upper respiratory tract infections (47.1%) and headache 
(42.7%). The authors concluded that long-term treatment with 
omalizumab is safe and well tolerated in children with allergic 
asthma, however further studies producing similar results would 
be required to verify this.
Pregnancy
No clinical studies of omalizumab in pregnant women have been 
performed but animal studies investigating the effects of high 
dose omalizumab (75 mg/kg) throughout reproduction have been 
conducted.  Maternal  toxicity,  embryotoxicity  or  teratogenicity 
were  not  evident  during  organogenesis  and  there  were  no 
adverse  effects  on  fetal  or  neonatal  growth  throughout  late 
gestation, delivery, and nursing. 
However,  animal  studies  are  not  always  predictive  of  human 
response. Omalizumab may cross the placental barrier and be 
excreted in breast milk, in a similar manner to IgG, and the risk of 
harm to a fetus or nursing infant is unknown. Omalizumab should 
only be used during pregnancy if absolutely required to maintain 
asthma control and caution should be exercised (Anon 2007). 
A  pregnancy  exposure  registry  has  been  initiated  to  monitor 
the  pregnancy  outcomes  in  women  exposed  to  omalizumab, 
including women who receive one or more doses of omalizumab 
within 8 weeks prior to conception or any time during pregnancy. 
These  women  will  be  followed  up  to  the  completion  of  their 
pregnancy and evaluation of their infants will be conducted at 
birth, 6, and 12 months (Anon 2006).
Outstanding questions with omalizumab
The  above  studies  have  demonstrated  that  omalizumab 
significantly  reduces  asthma  exacerbations  when  used  as  a 
steroid-sparing  agent  and  as  adjunctive  therapy  to  inhaled 
corticosteroids  and  LABAs  in  patients  with  moderate  and 
severe asthma, who are at step 3/4 in the GINA and BTS/SIGN 
guidelines. Its role in patients who are at step 5 in the BTS/SIGN 
and  GINA  guidelines  and  require  oral  corticosteroids  remains 
uncertain. Walker et al. (2006) describe that omalizumab had no 
significant effect on asthma exacerbations or reduction in daily 
oral steroid dose from data collected in one study (Holgate et al. Omalizumab | place in therapy
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2004) and there were insufficient data to justify the extrapolation 
of the findings to this subgroup. In the INNOVATE study (Humbert 
et al. 2005), which showed a significant reduction in the severe 
exacerbation  rate  and  the  emergency  visit  rate,  two  thirds 
of  patients  were  receiving  additional  controller  medications, 
including 22% on maintenance oral corticosteroids. The evidence 
for  the  use  of  omalizumab  in  patients  on  oral  corticosteroids 
remains limited, however, these are the very patients who suffer 
from refractory asthma and are being targeted for treatment with 
omalizumab. Further studies tailored towards the evaluating the 
efficacy of omalizumab in patients requiring oral corticosteroids 
are therefore required.
The size of the placebo effect is striking in these clinical trials. 
Patients receiving placebo were able to reduce the amount of 
inhaled  corticosteroid  they  required  by  significant  amounts 
(Walker et al. 2006). These effects may be due to close monitoring 
of patients throughout the trials resulting in better compliance 
with inhaled corticosteroids. This brings into question the true 
steroid-sparing effect of omalizumab and how much of its shown 
efficacy is related to study design and patient population.
The  steroid-sparing  effects  of  omalizumab  in  moderate-to-
severe  asthma,  although  statistically  significant  compared 
with placebo, remain quite modest (weighted mean difference   
–118 mcg beclomethasone equivalent per day, 95% CI –154,   
–84) and there was a high degree of variability between studies 
(Walker et al. 2006). This outcome has not been fully investigated 
in patients with severe asthma who are at higher risk of serious 
steroid side effects. The available evidence and the large placebo 
effect bring into doubt the cost effectiveness of omalizumab as 
a steroid-sparing agent. 
Omalizumab has an inconsistent effect on lung function with no 
definite benefit evident. This conflicting evidence may highlight 
the  unclear  relationship  between  improved  lung  function  and 
clinically  relevant  asthma  outcomes  (Qureshi  et  al.  1998; 
Wijnhoven et al. 2001). However, all other asthma medication 
has  been  licensed  on  the  basis  of  this  outcome.  The  true 
impact of omalizumab on lung function may be obscured by the 
accompanying  background  inhaled  therapy  used  throughout 
these studies.
The efficacy of omalizumab on asthma symptoms in patients 
with moderate and severe disease remains uncertain. Significant 
reductions in end of treatment symptoms scores occurred during 
the steroid stable phases of treatment (Busse et al. 2001; Solèr 
et al 2001; Holgate et al 2004), however, this only represented a 
reduction of approximately 10% from baseline scores (Walker 
et al. 2006). Nonetheless, there was indication that omalizumab 
is  more  beneficial  to  symptoms  in  the  more  severe  patient 
population  with  significant  reductions  from  baseline  symptom 
scores (Humbert et al. 2005).
Not  all  patients  respond  to  omalizumab  treatment,  with 
approximately 16% of patients with severe asthma unable to 
reduce their inhaled steroid dose by more than 25% throughout 
the steroid reduction phase (Walker et al. 2006). To identify those 
who would achieve greatest benefit from omalizumab, Bousquet 
et al. (2004) reviewed results from 1070 patients in two phase 
III studies (Busse et al. 2001; Solèr et al. 2001). A composite 
definition of response required no asthma exacerbation during   
16  weeks  of  treatment  and  response  in  at  least  one  of  the 
following:  reduced  symptom  scores,  reduced  usage  of 
medication,  improved  lung  function,  or  improved  quality  of 
life.  Three  baseline  variables  predictive  of  best  response  to 
add-on omalizumab were ascertained. A history of emergency 
asthma  treatment  in  the  past  year  was  the  most  predictive 
(P=0.015), followed by treatment with high-dose (≥800 mcg/day) 
beclomethasone  dipropionate  (P=0.037),  and  an  FEV1  ≤65% 
predicted  (P=0.072).  A  more  recent  analysis  (Bousquet  et  al. 
2007) using data from the INNOVATE study (Humbert et al. 2005) 
revealed the only pretreatment baseline characteristic predictive 
of a superior response to omalizumab was baseline total IgE, 
which was not found to be predictive in the study by Bousquet 
et  al.  (2004).  Although  subjective,  the  physicians’  overall   
assessment  of  treatment  was  determined  as  the  most   
meaningful  measure  of  response  to  omalizumab  therapy, 
with  approximately  61%  of  the  overall  omalizumab-treated 
population  identified  as  responders.  This  should  occur  at   
16  weeks,  which  would  allow  patients  to  achieve  maximum 
benefit (Bousquet et al. 2004). These results highlight the difficulty 
in trying to predict which patients will gain most benefit from 
omalizumab and therefore the resultant problem in optimizing 
the use of healthcare resources. Nonetheless, the recognition of 
the physicians’ overall assessment of treatment can potentially 
be used to determine whether treatment should continue beyond 
an initial 16-week trial.
Economic evidence
Omalizumab  is  an  expensive  novel  treatment  that  costs 
approximately £15 400 per patient per annum in the UK if the 
maximum recommended dose is administered every 2 weeks 
(NICE  2007).  A  retrospective  economic  analysis  using  data 
from  two  randomized  controlled  clinical  trials  (Busse  et  al. 
2001; Solèr et al. 2001) found the cost to achieve an additional 
successfully controlled day was $US523 and the daily cost to 
achieve at least a 0.5 point increase in the Asthma Quality of Life 
Questionnaire score was $US378 in 2003. Omalizumab could be 
cost saving if given to nonsmoking allergic asthmatic patients 
with poorly controlled symptoms despite maximal therapy who 
are hospitalized five or more times or for 20 days or more each 
year (Oba & Salzman 2004).
A  Markov  model  comparing  lifelong  standard  therapy  with  a 
treatment  period  of  omalizumab  add-on  therapy  followed  by 
standard therapy was developed using data from the INNOVATE 
study  (Humbert  et  al.  2005)  and  adapted  towards  a  Swedish 
societal  prospective.  This  revealed  that  omalizumab  add-on 
therapy cost an additional €42 754 for 0.76 additional quality-
adjusted  life  years  (QALYs)  resulting  in  an  incremental  cost-
effectiveness ratio (ICER) of €56 091 (95% CI €31 328, €120 552). 
The analysis concluded that omalizumab provides cost offsets 
and  may  have  an  attractive  ICER  in  treating  severe  allergic 
asthma (Dewilde et al. 2006).64
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A  lower  ICER  of  €31 209  (95%  CI  €27 739,  €40 840)  was   
determined for adding omalizumab to standard therapy using 
data  from  the  real-life  1-year  randomized  open-label  study 
(ETOPA) and using Canada as a reference country (Brown et al. 
2007). Only patients receiving high-dose inhaled corticosteroids 
plus LABA were included in the analysis.
The NICE Evidence Review Group (ERG) calculated ICERs for 
different scenarios using data from the INNOVATE (Humbert et 
al. 2005) primary intention-to-treat population that ranged from   
£33 300  to  £40 900  per  QALY  gained  (NICE  2007).  Scenario 
analyses  for  the  high-risk  hospitalization  subgroup  ranged 
from £29 800 to £34 300 per QALY gained. The ERG’s amended 
probabilistic  sensitivity  analysis  showed  a  mean  ICER  of   
£38 900 per QALY gained. They estimated omalizumab as add-
on therapy to have a 23.6% probability of being cost effective, 
using a threshold willingness to pay of £30 000 per QALY (NICE 
2007). In the NICE final appraisal determination of omalizumab 
for severe persistent allergic asthma the Appraisal Committee 
concluded that the ICER was higher than acceptable for patients 
with  severe  persistent  allergic  asthma  (NICE  2007).  They  did, 
however,  agree  that  for  a  narrowly  defined  severely  affected 
group of asthmatics, at an elevated risk of asthma mortality, cost-
effective treatment with omalizumab was possible if therapy was 
discontinued in nonresponders at 16 weeks and if vial wastage 
could be minimized to reduce costs. 
Patient group/population
The  NICE  Appraisal  Committee  (NICE  2007)  in  England  and 
Wales recommends that omalizumab add-on therapy is used as 
an option for the treatment of asthma in adults and adolescents   
(12 years and older) with severe unstable disease. This is defined 
as those who have had either two or more severe exacerbations 
of asthma requiring hospital admission within the previous year, or 
three or more severe exacerbations of asthma within the previous 
year, at least one of which required admission to hospital, and 
a further two which required treatment or monitoring in excess 
of  the  patients’  usual  regimen  in  an  accident  and  emergency 
unit. These patients must have a full trial of, and documented 
compliance with, inhaled high-dose corticosteroids and LABA in 
addition to leukotriene receptor antagonists, theophyllines, oral 
corticosteroids, and oral beta2 agonists, and smoking cessation 
where  clinically  appropriate.  They  require  confirmation  of  IgE-
mediated allergy to a perennial allergen by clinical history and 
allergy  skin  testing.  Omalizumab  should  be  discontinued  at   
16 weeks in patients who have not shown an adequate response 
to therapy (NICE 2007).
The  BTS/SIGN  guidelines  state  that  there  are  no  active 
comparative studies and it is therefore not yet possible to place 
omalizumab  in  the  stepwise  treatment  of  asthma  (BTS,SIGN 
2007).  However,  the  worldwide  GINA  guidelines  include  the 
addition of omalizumab for patients whose symptoms are not 
controlled  despite  combination  therapy  including  high  doses 
of  inhaled  corticosteroids,  LABA,  and  oral  steroid  treatment   
(GINA 2006b).
There is insufficient evidence to support the use of omalizumab 
in children with severe persistent allergic asthma. Although two 
studies in this population have shown similar results to studies 
in  adolescents  and  adults,  further  evaluation  of  this  agent  in 
children is required.
Dosage, administration, and formulations
Omalizumab (Xolair) is available for injection in 150 mg vials of 
powder for reconstitution. Doses ranging from 150 to 375 mg are 
administered subcutaneously every 2 or 4 weeks. The dose of 
omalizumab (mg) and dosing frequency are determined by serum 
total  IgE  (IU/mL)  measured  before  the  start  of  treatment  and 
bodyweight (kg). Dose determination charts are used to assign 
the  appropriate  dose  (Tables  5a  and  b).  Doses  of  more  than   
150 mg are divided among more than one injection site, with not 
more than 150 mg per site.
It  is  unclear  whether  omalizumab  is  therapeutically  effective 
in  obese  patients  whose  bodyweight  falls  outside  the  dosing 
guidelines. Kwong and Jones (2006) describe how the maximum 
dose of omalizumab reduced the systemic steroid requirements 
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Pretreatment 
serum IgE  
(IU/mL)
Bodyweight
30–60 >60–70 >70–90 >90–150
≥30–100
>100–200 225
>200–300 225 225 300
>300–400 225 225 300
>400–500 300 300 375
>500–600 300 375 Do not use
>600–700 375
   Table 5b |   Omalizumab dose (mg) administered by 
subcutaneous injection every 2 weeks for 
adults and adolescents (12 years of age and 
older) with asthma (Anon. 2007) 
Pretreatment 
serum IgE  
(IU/mL)
Bodyweight (kg)
30–60 >60–70 >70–90 >90–150
≥30–100 150 150 150 300
>100–200 300 300 300
>200–300 300 See below
>300–400
>400–500
>500–600
   Table 5a |   Omalizumab dose (mg) administered by 
subcutaneous injection every 4 weeks for 
adults and adolescents (12 years of age and 
older) with asthma (Anon. 2007) Omalizumab | place in therapy
of two obese pediatric patients with severe persistent asthma, 
and  one  patient  required  fewer  daily  inhaled  corticosteroids. 
Further studies into the efficacy of omalizumab in patients whose 
weight falls outside the dosing guidelines are required.
Place in therapy
Current  clinical  evidence  indicates  that  omalizumab  is  an   
effective  add-on  therapy  in  patients  with  severe  persistent   
allergic  asthma.  This  is  demonstrated  by  improvements  in 
important  clinical  outcomes  such  as  exacerbation  rates, 
emergency  visit  rates,  symptom  scores,  and  quality  of  life   
scores.  Omalizumab  gives  physicians  a  further  therapeutic 
option  in  the  management  of  patients  with  therapy-resistant 
disease  and  it  is  this  subgroup  that  has  the  potential  to 
benefit the most. However, the role of omalizumab in patients   
requiring  maintenance  oral  steroid  therapy  remains  unclear 
and further studies are required to demonstrate efficacy in this 
population.  Difficulty  in  identifying  patients  who  will  respond 
to this expensive novel therapy prior to treatment also creates 
problems  with  resource  utilization.  NICE  has  recommended 
that  cost-effective  treatment  with  omalizumab  is  possible  in 
severe  adult  asthmatics  with  a  high  risk  of  asthma-related 
mortality provided that treatment is discontinued in nonresponders 
after  16  weeks.  Additional  evidence  is  required  to  assess 
the  impact  and  safety  of  omalizumab  in  children  with  severe   
allergic asthma.
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